RxDoctor Payments Data

Andrea Lamberson, MD

Family Medicine · Birmingham, ALNPI 1609974948

Payments from drug & device makers

$6,421in general payments, 2019–2025

Across 443 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$986
  • GSK$820
  • Lilly USA, LLC$553
  • Bausch Health US, LLC$521
  • AstraZeneca$342
  • Amgen$262
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,34799%
  • Education$140%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,421 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$40,269
Medicare patients
130
Services billed
730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$73,632
JardianceEmpagliflozin54$51,428
FarxigaDapagliflozin Propanediol53$49,521
EliquisApixaban59$47,879
VraylarCariprazine Hcl25$34,356
JanuviaSitagliptin Phosphate47$32,382
TrulicityDulaglutide25$29,187
MounjaroTirzepatide25$25,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$24,737
KerendiaFinerenone33$22,940
MyrbetriqMirabegron28$21,276
GemtesaVibegron29$18,755
LinzessLinaclotide31$18,581
Aimovig AutoinjectorErenumab-Aooe16$14,112
Breo ElliptaFluticasone/Vilanterol22$11,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$253$73,63268 claims
AbbVieVraylar, Linzess, Fetzima, Synthroid$986$61,572102 claims
AstraZenecaFarxiga, Breztri Aerosphere$342$59,06769 claims
Lilly USA, LLCTrulicity, Mounjaro$553$54,77850 claims
Boehringer IngelheimJardiance$172$51,42854 claims
PfizerEliquis$226$47,87959 claims
MerckJanuvia, Belsomra$20$39,51564 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$820$39,27466 claims
BayerKerendia$128$22,94033 claims
Astellas Pharma US IncMyrbetriq$11$21,27628 claims
Sumitomo Pharma America, Inc.Gemtesa$256$18,75529 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$188$10,91023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →